Latest1 information on COVID-19

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

Not Recruiting

Trial ID: NCT00185848

Age - 18 Years-N/A Condition - Brain (Central Nervous System, CNS) Cancers Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.

Official Title

Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.

Stanford Investigator(s)

Sanjiv Sam Gambhir, MD, PhD

Michael L. Goris

Eligibility


Inclusion Criteria:

- Clinical diagnosis of brain tumor or rheumatoid arthritis

Exclusion Criteria:

- Below 18 years of age

View More
View Less

Intervention(s):

radiation: [18F]FHBG

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
ccto-office@stanford.edu
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine